Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

@article{Jnne2014PhaseIS,
  title={Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.},
  author={Pasi Antero J{\"a}nne and Roger B. Cohen and A. Douglas Laird and Sandrine Mac{\'e} and Jeffrey A. Engelman and Rodrigo Ruiz-Soto and Kevin Rockich and Jianbo Xu and Geoffrey I. Shapiro and Pablo Mart{\'i}nez and E Felip},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2014},
  volume={9 3},
  pages={316-23}
}
INTRODUCTION The primary objectives of this phase I study were to evaluate the safety and maximum tolerated dose (MTD) of SAR245409, a pan-class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, combined with erlotinib in patients with advanced solid tumors. METHODS Forty-six patients with advanced solid tumors were enrolled. Patients with lung cancer (n = 37) had received an epidermal growth factor receptor (EGFR) inhibitor before study entry. SAR245409 30, 50… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…